| Document |
Document Title |
|
WO/2019/171278A1 |
The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particul...
|
|
WO/2019/158485A1 |
The invention provides a method for synthesizing musk macrocycles comprising contacting an easily accessible diene starting materials bearing a Z-olefin moiety and performing a ring closing metathesis reaction in the presence of a Group ...
|
|
WO/2019/144132A1 |
Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen rece...
|
|
WO/2019/124523A1 |
In the present invention, an efficacious therapy for glaucoma is discovered and provided as a medicine. A combination of the present invention, in particular a combination of 2-propanyl 4-{(3S, 5aR, 6R, 7R, 8aS)-6-[(1E, 3R)-4-(2, 5-diflu...
|
|
WO/2019/113019A2 |
This invention relates generally to the synthesis of E-macrocycles using stereoretentive ruthenium olefin metathesis catalysts supported by dithioiate ligands. Macrocycles were generated with excellent selectivity (>99% E) and in moderat...
|
|
WO/2019/104850A1 |
Disclosed is a method for preparing a lactone compound, for which a cyclic ketone compound serves as a raw material; in an oxygen-containing atmosphere, a cyclic organic nitroxide free radical serves as a catalyst, and a certain amount o...
|
|
WO/2019/092030A1 |
The present invention relates to novel chlorotonil derivatives of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections and malaria.
|
|
WO/2019/087208A1 |
The present invention provides a novel and improved process for the preparation of Tavaborole of Formula (I) and its pharmaceutically acceptable salts. The present invention also provides novel intermediates and process for the preparati...
|
|
WO/2019/072669A1 |
The present invention relates to a method for preparing a compound of formula (I). The present invention also relates to compounds of formula (A) or a compound in the form of a stereoisomer. The present invention further relates to the u...
|
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
|
WO/2018/197963A1 |
The invention relates to a method for the preparation of cyclic compounds in the metathesis of olefins from acyclic dienes comprising terminal and/or non-terminal C=C double bonds; the invention also relates to the use of homogeneous rut...
|
|
WO/2018/175418A1 |
16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).
|
|
WO/2018/150421A1 |
The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).
|
|
WO/2018/100515A1 |
The invention relates to novel ruthenium complexes of formula (9). The invention also relates to the method for preparation of novel metal complexes of formula (9) and their use in olefin metathesis reactions.
|
|
WO/2018/084120A1 |
A benzoic acid derivative and a dehydration-condensation agent, each of which is represented by formula (I) or (II). In formulae (I) and (II), R1 represents a haloalkyl group, a halogen atom or a cyano group; and R2, R3 and R4 independen...
|
|
WO/2018/063049A1 |
Disclosed is an equipment and a process for processing of a product stream (a) comprising acetic acid, unreacted cyclohexanone, reaction water and organic heavy ends, said product stream (a) being yielded in a caprolactone production whe...
|
|
WO/2018/049733A1 |
A method for preparing ε-caprolactone is provided. The method comprises the following steps: adding a cyclohexanone, an auxiliary oxidant, a certain amount of catalyst and a molecular oxygen as an oxidant into a certain amount of organi...
|
|
WO/2018/003945A1 |
[Problem] Provided are a method for producing 2-propanil 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-h
ydroxy-1-butene-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxe
pine-3-yl}butanoate, which can solve various problems desc...
|
|
WO/2017/184984A1 |
Molecular characterization of disease has become the dominant trend in modern medicine, and it has recently become increasingly important to obtain qPCR, microarray, and next-generation sequencing (NGS) data for both research and clinica...
|
|
WO/2017/160925A1 |
Disclosed herein are compounds of Formulae (I), and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
|
|
WO/2017/153455A1 |
A process for preparing a macrocyclic lactone comprising 14 to 17 ring carbon atoms, the process comprising the steps of i) subjecting a reaction mixture comprising an olefin-containing random polyester, formed by metathesis to a cyclo-d...
|
|
WO/2017/155442A1 |
Disclosed is a production equipment for production of a caprolactone by reaction between peracetic acid, produced from acetic acid and hydrogen peroxide, and cyclohexanone, said equipment being split into a first section (Fig. 1) wherein...
|
|
WO/2017/155441A1 |
Disclosed is a production equipment for production of a caprolactone by reaction between peracetic acid, produced from acetic acid and hydrogen peroxide, and cyclohexanone, said equipment being split into a first section (Fig. 1) wherein...
|
|
WO/2017/152099A1 |
The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating immune response processes, and methods of treating disease, disorders, and symptoms thereof.
|
|
WO/2017/124184A1 |
The present invention provides a new compound of formula (I): extracted from a seaweed, and its use for inhibiting the growth of cancer cells, as well as methods for its extraction and isolation.
|
|
WO/2017/118375A1 |
Disclosed in the present invention is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.
|
|
WO/2017/116939A1 |
The invention relates to macrocyclic picolinamides of Formula (I) and their use as fungicides. (Formula (I))
|
|
WO/2017/116954A1 |
The invention relates to macrocyclic picolinamides of Formula (I) and their use as fungicides.
|
|
WO/2017/116956A1 |
This disclosure relates to macrocyclic picolinamides of Formula (I) and their use as fungicides.
|
|
WO/2017/080292A1 |
A trifluoromethyl-modified (+)-Patulolide C. By adding a trifluoromethyl group to (+)-Patulolide C, it is expected that favorable antibacterial and anti-inflammatory activity can be obtained.
|
|
WO/2017/040769A1 |
Compositions and methods for the production of derivatives of spinosyns are provided. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and/or nematodes and are useful in the agricultural and anim...
|
|
WO/2017/040763A1 |
Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include spinosyn derivatives functionalized on the C5-C6 double bond of th...
|
|
WO/2017/040878A1 |
Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-13,14 double bond to provide an addi...
|
|
WO/2017/040882A1 |
Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include spinosyn derivatives functionalized on the C5-C6 double bond of sp...
|
|
WO/2017/030450A1 |
A method of increasing the rigidity of PIM homo- or co-polymers including repeating units containing at least one biscatechol monomer having a fused spiro-bisindane (SBI) ring system of Formula (I), the SBI ring system including a bicycl...
|
|
WO/2017/026643A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure is effective in preparing an organic...
|
|
WO/2017/019561A1 |
A compound having the structure (I) and (II).
|
|
WO/2017/019550A1 |
A compound having the structure (I) or (II).
|
|
WO/2016/193134A1 |
The invention relates to a method for producing cyclic esters of general formula (I.a) or (I.b) in the presence of at least one high-boiling metal alkoxide catalyst. The invention further relates to the stereoisomers of 18-methyl-1-oxacy...
|
|
WO/2016/196256A2 |
This disclosure is directed to non-aromatic difluoro analogues of resorcylic acid lactones, pharmaceutical compositions comprising non-aromatic difluoro analogues of resorcylic acid lactones, and methods of treatment comprising non-aroma...
|
|
WO/2016/167698A1 |
Disclosed is a catalysed Baeyer-Villiger oxidation of cyclic ketones yielding corresponding lactones. Hydrogen peroxide is used as oxidant and said oxidation is catalysed by a catalytically active amount of at least one catalyst comprisi...
|
|
WO/2016/128991A1 |
The invention relates to the compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII, or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates...
|
|
WO/2016/104630A1 |
The present invention pertains to: a condensed heterocyclic compound having an inhibitory effect on enteropeptidase, the condensed heterocyclic compound being useful in the treatment or prevention of obesity, diabetes, and the like; and ...
|
|
WO/2016/068220A1 |
Provided are: eushearilides; a method for producing eushearilides; a production intermediate; and a pharmaceutical composition containing eushearilides. By having the Wittig reaction process, Mukaiyama Aldol reaction process and Macrolac...
|
|
WO/2016/019587A1 |
Provided are compounds of the structural formula (I), the pharmaceutically acceptable salts thereof, and the use as agonists of G-protein coupled receptor 40 (GPR40) for the treatment of Type 2 diabetes mellitus, and of conditions that a...
|
|
WO/2016/018153A1 |
The present invention relates to novel compounds, comprising an 8-or 9- membered cyclic structure, wherein an (E)-1,4-dioxo-but-2-ene moiety is embedded in said cyclic structure and to pharmaceutical compositions comprising these compoun...
|
|
WO/2016/014797A1 |
The invention relates to novel compounds and pharmaceutical preparations thereof, as well as methods of making and using these compounds. The invention further relates to methods of treating or preventing disease using the novel compound...
|
|
WO/2016/005049A1 |
The present invention relates to a compound according to general formula (I), which exhibits bioactivity; methods for the production of the compound; to pharmaceutical compositions comprising one or more of the compound(s); and to the us...
|
|
WO/2015/145152A1 |
The invention providesnovel macrolide compounds of formula (I) and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers), and prodrugs. In formula (I), R1 is hydrogen or an ester-forming group; R2 is methyl o...
|
|
WO/2015/083185A1 |
The present invention discloses an improved oxidation process using carbon nitride nanotubes as metal free catalyst and molecular O2 as the oxidant to obtain desired adipic acid and other oxygenated hydrocarbons with improved conversion ...
|
